Literature DB >> 8887989

Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain.

L Romero1, N Bel, F Artigas, C de Montigny, P Blier.   

Abstract

In microdialysis studies, somatodendritic 5-HT1A receptors in the dorsal raphe nucleus (DRN) were activated by the local infusion of 50 microM citalopram, a selective 5-HT reuptake inhibitor (SSRI). This reduced extracellular 5-HT by about 50% in dorsal striatum, an area receiving 5-HT afferents exclusively from the DRN. (-)Pindolol dose-dependently attenuated this citalopram-induced reduction of striatal extracellular 5-HT. Consistent with its 5-HT reuptake blocking properties, single doses of the SSRI paroxetine (1 and 3 mg/kg IP) and citalopram (1 mg/kg IP) significantly elevated extracellular 5-HT in the dorsal striatum. Pretreatment with (-)pindolol (15 mg/kg IP) potentiated the effect of 3 mg/kg paroxetine and 1 mg/kg citalopram on striatal extracellular 5-HT. A 2-day treatment with 10 mg/kg/day (SC) of paroxetine reduced by 60% the spontaneous activity of 5-HT neurons of the DRN. However, 5-HT neurons displayed normal activity in rats treated with paroxetine and (-)pindolol for 2 days. The inhibitory effect of LSD on 5-HT neuronal firing activity was also markedly attenuated in (-)pindolol-treated rats, indicating that somatodendritic 5-HT1A receptors were blocked by (-)pindolol. To determine whether (-)pindolol also blocked postsynaptic 5-HT1A receptors in hippocampus, 5-HT and the prototypical 5-HT1A agonist 8-OH-DPAT were applied by microiontophoresis onto CA3 pyramidal neurons following the same treatment. (-)Pindolol did not modify the responsiveness of these neurons to 5-HT and 8-OH-DPAT. Taken together, these results indicate that (-)pindolol can potentiate the effects of an SSRI on extracellular 5-HT concentration by preventing the activation of somatodendritic 5-HT1A autoreceptors resulting from the blockade of the 5-HT transporter in the raphe. This presumably leads to enhanced 5-HT neurotransmission because (-)pindolol would not alter the responsiveness of certain postsynaptic 5-HT1A receptors, such as those located on hippocampal CA3 pyramidal neurons. These results provide a neurobiological basis for the reported potentiation of certain antidepressant drugs by pindolol in major depression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887989     DOI: 10.1016/0893-133X(95)00240-E

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  26 in total

1.  Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers.

Authors:  S T Szabo; C de Montigny; P Blier
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Effects of sustained (+/-)pindolol administration on serotonin neurotransmission in rats.

Authors:  N Haddjeri; P Blier
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

Review 3.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

4.  Delayed Antidepressant Efficacy and the Desensitization Hypothesis.

Authors:  Kathryn G Commons; Sofia E Linnros
Journal:  ACS Chem Neurosci       Date:  2019-03-11       Impact factor: 4.418

5.  Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.

Authors:  M C Scorza; L Lladó-Pelfort; S Oller; R Cortés; D Puigdemont; M J Portella; R Pérez-Egea; E Alvarez; P Celada; V Pérez; F Artigas
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

6.  Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.

Authors:  Khanh Q Nguyen; Yoshihiro Tohyama; Arata Watanabe; Shu Hasegawa; Ivan Skelin; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-27       Impact factor: 3.921

Review 7.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

8.  Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers.

Authors:  Rui Tao; Mary Rudacille; Gongliang Zhang; Zhiyuan Ma
Journal:  Neuropsychopharmacology       Date:  2014-02-28       Impact factor: 7.853

Review 9.  The role of different serotonin receptor subtypes in seizure susceptibility.

Authors:  Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian
Journal:  Exp Brain Res       Date:  2013-11-14       Impact factor: 1.972

10.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.